 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq: AVEO, a commercial and clinical development stage biopharmaceutical company, today announced results from a randomized confirmatory Phase 2 study of ficlatuzumab as a single agent or in combination with cetuximab ERBITUX, an EGFR-targeted antibody, in patients who relapsed or were refractory to prior immunotherapy, chemotherapy, and cetuximab pan-refractory with metastatic head and neck squamous cell carcinoma HNSCC. Ficlatuzumab is AVEOs 